9-PAHSA
目录号 : GC403259-PAHSA是一种内源性生物活性脂质，属于脂肪酸类（FAHFAs）。
Cas No.:1481636-31-0
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
9-PAHSA is an endogenous bioactive lipid from the FAHFAs class [1]. 9-PAHSA modulates GPCR signaling (such as activating GPR40/GPR120 or antagonizing chemokine receptors) and alleviates lipotoxicity and mitochondrial dysfunction in hepatocytes [2-3]. 9-PAHSA is mainly used to study the mechanism of diabetes and ischemia-reperfusion injury [4].
In primary murine hepatocytes (PMH), 9-PAHSA (5-40μM; 24h) treatment improved the viability of the steatotic PMH [5]. In RAW 264.7 cells, 9-PAHSA (2-10μM; 24h) treatment inhibited LPS-stimulated IL-1β and IL-6 gene expression [6].
In db/db mice, 9-PAHSA (50mg/kg; ig; 4weeks) treatment lowered glycemia [7]. In ischemia/reperfusion (I/R) injury mice model, 9-PAHSA (40mg/kg, 80mg/kg; ip; single injection) treatment alleviated myocardial I/R injury [8].
References:
[1]. Pflimlin E, Bielohuby M, Korn M, et al. Acute and repeated treatment with 5-PAHSA or 9-PAHSA isomers does not improve glucose control in mice[J]. Cell metabolism, 2018, 28(2): 217-227. e13.
[2]. Wohlfart P, Chehtane M, Luna E, et al. 9-PAHSA displays a weak anti-inflammatory potential mediated by specific antagonism of chemokine G protein-coupled receptors[J]. Frontiers in Drug Discovery, 2023, 3: 1138461.
[3]. Wang Y M, Liu H X, Fang N Y. 9-PAHSA promotes browning of white fat via activating G-protein-coupled receptor 120 and inhibiting lipopolysaccharide/NF-kappa B pathway[J]. Biochemical and Biophysical Research Communications, 2018, 506(1): 153-160.
[4]. Lupu C, Patel M M, Lupu F. Insights into the functional role of ADTRP (androgen-dependent TFPI-regulating protein) in health and disease[J]. International Journal of Molecular Sciences, 2021, 22(9): 4451.
[5]. Schultz Moreira A R, Rüschenbaum S, Schefczyk S, et al. 9-PAHSA prevents mitochondrial dysfunction and increases the viability of steatotic hepatocytes[J]. International journal of molecular sciences, 2020, 21(21): 8279.
[6]. Dongoran R A, Lin T J, Byekyet A, et al. Determination of major endogenous FAHFAs in healthy human circulation: the correlations with several circulating cardiovascular-related biomarkers and anti-inflammatory effects on RAW 264.7 cells[J]. Biomolecules, 2020, 10(12): 1689.
[7]. Wang Y M, Mi S L, Jin H, et al. 9-PAHSA improves cardiovascular complications by promoting autophagic flux and reducing myocardial hypertrophy in Db/Db mice[J]. Frontiers in pharmacology, 2021, 12: 754387.
[8]. Liu W, Hu J, Wang Y, et al. 9-PAHSA ameliorates microvascular damage during cardiac ischaemia/reperfusion injury by promoting LKB1/AMPK/ULK1-mediated autophagy-dependent STING degradation[J]. Phytomedicine, 2025, 136: 156241.
9-PAHSA是一种内源性生物活性脂质，属于脂肪酸类（FAHFAs） [1]。9-PAHSA能够调节GPCR信号传导（例如激活GPR40/GPR120或拮抗趋化因子受体），并减轻肝细胞的脂毒性和线粒体功能障碍 [2-3]。9-PAHSA主要用于糖尿病和缺血再灌注损伤机制研究 [4]。
在原代小鼠肝细胞（PMH）中，9-PAHSA（5-40μM；24h）处理可提高脂肪变性PMH的活力 [5]。在 RAW 264.7细胞中，9-PAHSA（2-10μM；24h）处理可抑制LPS刺激的IL-1β和IL-6基因表达 [6]。
在db/db小鼠中，9-PAHSA（50mg/kg；ig；4周）治疗可降低血糖 [7]。在缺血/再灌注（I/R）损伤小鼠模型中，9-PAHSA（40mg/kg，80mg/kg；ip；单次注射）治疗可减轻心肌I/R损伤 [8]。
| Cell experiment [1]: | |
Cell lines | Primary murine hepatocytes (PMH) |
Preparation Method | PMH were cultured overnight in 96-well plates at a density of 5 × 104 cells/well. After induction of steatosis and treatment with 9-PAHSA, cell viability was determined using the WST-1 Cell Proliferation Reagent Kit. Absorbance was measured using a spectrophotometer. |
Reaction Conditions | 5-40μM; 24h |
Applications | 9-PAHSA treatment improved the viability of the steatotic primary murine hepatocytes. |
| Animal experiment [2]: | |
Animal models | db/db mice |
Preparation Method | 32-week-old mice were randomly assigned into groups as follows: ctrl + veh, db/db + veh, db/db+9-PAHSA (50mg/kg per day) (n = 9 mice for each group). 9-PAHSA was given to mice by gavage once a day for 4 weeks. The veh groups were given with the same volume of vehicle (50% PEG400, 0.5% Tween-80, 49.5% H2O) at the corresponding time points. |
Dosage form | 50mg/kg; ig; 4weeks |
Applications | 9-PAHSA administration lowered glycemia in db/db mice. |
References: | |
| Cas No. | 1481636-31-0 | SDF | |
| Canonical SMILES | OC(CCCCCCCC(OC(CCCCCCCCCCCCCCC)=O)CCCCCCCCC)=O | ||
| 分子式 | C34H66O4 | 分子量 | 538.9 |
| 溶解度 | DMF: 20 mg/ml,DMSO: 15 mg/ml,Ethanol: 20 mg/ml,Ethanol:PBS(pH 7.2) (1:1): 0.5 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.8556 mL | 9.2782 mL | 18.5563 mL |
| 5 mM | 0.3711 mL | 1.8556 mL | 3.7113 mL |
| 10 mM | 0.1856 mL | 0.9278 mL | 1.8556 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet